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Since the ~u~rodu~~~o 
nary angioplasty more 
unchallenged position 
disease. Advances in 
experience and technical skill of the practitioners have 
improved initial success rates. Simultaneo 
rates have substantially decreased (2-5). 
closure of the dilated vessel occurring in c 
procedure is still one of the main hazards of the operation 
(2-5). 
Coronary angioplasty generally results in disruption of 
the fibrous cap of the coronary artery plaque (63. During 
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me of early woun 
deling of the coronary stenosis occurs as 
e of the orga~iza~ioi~ :? this thrombotic 
leading to improved vessel geometry in the m 
cases. Abrupt closure of rhe coronary artery, 
be closely related to the angioplasty proce 
concomitant antithrombotic therapy with he 
rin, vessel reclosure may be ed by overshooting of the 
thrombus growth (4,6). It see uite reasonable, therefore, 
that thrombolysis together with low pressure redilations may 
improve the early success rate of coronary angiop~asty. 
The present study was designed to determine I) whether 
coronary artery a 
plasty and 2) whether th 
remains patent or tends to 
cause the pivotal role of thr 
undergoing combined thrombolysis and redilation. 
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Table 1. Patient Characterislics 
Padents Undergoing Patients Undergoing 
Thrombolysis for Thrombolysis With 
Patients Screened Abrupt Occlusion Coagulation Analysis 
(Feb. 1987~July 1988) (Feb. 1987~July 1988) (May 1987~July 1988) 
Patients (nr.) 565 27 21 
Gender (femNmale) 761489 4123 3118 
Palients excluded before 51 - 
study entry* 
Dilated vessels lOl/68/278/67 914/141- 7/3/111- 
(RCA/LCx/LAD/muldple) 
AEe (Yr) 56.4 + 8.9 55.8 + 13.3 58.3 r 8.9 
Height (cm) 172.5 + 8.7 175.1 r 5.9 174.8 f. 6.1 
Weight (kg) 75.9 r 10.4 80.7 + 8.6 78.9 r 8.7 
*For technical reasons such as bypass graft angioplasty or coronary stenosis not passed with the guide wire or 
with the balloon catheter. Data are mean values 2 SD. LA = left aalerior descending coronary artery; LCx = left 
circumflex coronary artery: RCA = right coronary artery. 
Selection ofpatients. Patients were selected from a 
of 565 consecutive patients who underwent coronary 
plasty for severe (>70%) coronary artery stenosi 
February 1987 through July 1988. All patients were pre- 
treated with 500 mg of oral aspirin, oral nitrates and a 
calcium channei blocker. Only those patients were selected 
for study entry who after angioplasty had abrupt closure of 
the vessel while they were still in the catheterization labo- 
ratory. Patients in whom it was not possible to advance the 
catheter over the stenosis were excluded from study. Pa- 
tients were also excluded for the following reasons: 1) 
multiple vessel angioplasty, 2) angioplasty of a bypass graft. 
3) unstable circulatory conditions, 4) history of recent gas- 
trointestinal b eeding, 5) history of cerebrovascular acci- 
dent, 6) known bleeding tendency, and 7) all other contrain- 
dications to thrombolytic therapy. Patients were also 
excluded if a large intimal dissection with a clearly visible 
intimal f ap was angiographically identified tohave obviously 
caused the vessel closure. Before the patients were entered 
into the study, witnessed oral consent was obtained from all 
patients. The protocol was approved before the study by our 
institutional ethical committee. 
Study patients (Table 1). From February 1987 through 
July 1988, 565 patients underwent coronary angioplasty. 
Fifty-one patients were not entered into the study because 
their stenosis was not crossed, a bypass graft was dilated or 
one of the other exclusion criteria for study entry was 
present; 67 additional patients (11.9%) were excluded for 
multiple vessel dilations. Twenty-seven (6%) of the remain- 
ing 447 patients had acute thrombotic coronary occlusion 
during the angioplasty procedure. These 27 patients under- 
went combined intracoronarylintravenous thrombo!ysis 
combined with repeat low pressure balloon inflations. Be- 
ginning May 1987, detailed coagulation a d fibrinolysis anal- 
yses were performed (21 of the 27 patients). Two additional 
patients (0.5%) suffered acute coronary occlusion obviously 
resulting from the presence of a coronary flap; they bot 
cy aortocoronary bypass grafting. 
la&y. This was perfo 
guiding catheter, stee 
5F monorail balloon catheter positioned th 
groin. Before the procedure was started, 10 
tionated heparin was administered intraven 
Four electrocardiographic (ECG) leads (including one epi- 
cardial lead) as well as aortic and pulmonary wedge pres- 
sures were coot~~~o~s~y monitore . A~g~op~asty was per- 
formed with balloon inflation pressures ranging from 3 to 12 
atm. All procedures were carried out with surgical standby. 
diagnosis of acute thrombotic losure was based on the 
following criteria: 1) a slowly progressing structure sur- 
rounded by contrast medium that finally completely ob- 
structed the coronary bed, or 2) an intraluminal filling defect 
clearly visible on the fluoroscopic mage of the angiogram 
that finally led to complete obstruction of the vessel lumen. 
Both criteria were accompanied by grade 0 or 1 flow accord- 
ing to the grading scale introduced by the Thrombolysis in
Myocardial Infarction (TIMI) investigators (11). 
Thrombolytic herapy. After thrombotic vessel occlusion 
had been diagnosed, an intracoronary injection of 5,000 to 
10,000 IU unfractionated heparin (Liquemin, Hoffman La- 
Roche AC) was given in doses of 5,000 IU through the 
guiding catheter (Fig. 1) and redilation was performed with 
balloon pressures of 2 to 4 atm. The balloon catheter was 
then removed and thrombolytic therapy commenced with 
the least possible time delay. 
Thrombolysis wus smwd with intracoronary administra- 
tion of 20 mg single chain, recombinant tissue-type i- 
nogen activator (&PA) (Actilyse, Dr. Karl Thomae, GmbH) 
infused over a 5 min period through the guiding catheter and 
was then continued with a 60 min intravenous infusion of 50 
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acute thrombotlc 
coronary OCClUSlOn 
5 -10000IE heparin 
i.c. bolus 
~~~~~~ B. Study design. d = day: i-c. = ~~~r~~~r~fl~~r~~ IE = 
internationai units; i.v. = intravenous: PKA = perc~ntaneous 
tra~s~Mm~~a1 coronary angioptasty: t = time: TAT = thrombin- 
mg. This regimen was selected in actor 
~rn~~~ys~s, the guide wire was IcJ in 
place. As soon as the patients reported recurrence & chest 
pain, an additional injection of contrast 
If the vessel had reoccluded, the angio 
atm. As soon as reopening of the vess 
the angioplasty catheter was again I 
indicated, this proce 
had been achieved o 
evident. 
Final angioplasty failure was okays assumed if lastirzg 
patency was not achieved within 60 rnin afiler rhe start of 
thrombo~ysis. Degenclling on the estimated amount of myo- 
cardium at risk, patients then either un 
bypass grafting or the vessel was left occ 
treated in the coronary care unit until c 
had returned to normal. In case of persistent patency of the 
vessel, an additional intracoronary injection of 5,000 1U 
heparin was administered through the guiding catheter and 
the catheter was then removed, with the arterial and venous 
catheter sheaths left in place. The patients were then trans- 
ferred to the coronary care unit, where they were followed 
up for 24 h and the KG and cardiac enzyme leve 
repeatedly monitored. 
Coronary angiography was repeated 
24 to 34 h later (Fig. 1). Until reexamination all patients were 
given a continuous infusion of 1,250 W/h heparin through 
the catheter sheaths. In addition, patients were given an 
intravenous daily infusion of 75 mg intravenous nitrates, 30 
od cell counts were 
ter or the need for a blood transfusion of ~-2 U of 
Statistical evaluations were per- 
formed with Fisher’s exact test and Fisher’s t test. 
values ~0.05 were regarded as statistically sig 
reported p valves are two sided and not adjusted 
testing. 
Dersion. In
22 occlusion 
closely related to angioplasty, the vessel was patent at 
discharge from the cat~eteri~a~~on lab (FiP. 2). Two 
of the remanding 5 patients underwe gef cy bypass 
grafting. In these two patients thrombolysis was ~~tagoaized 
by giving I million klU aprotinin as an intravenous 
over a 5 min period foollowed by a continuous intrav 
infusion of B million klU/h aprotinin. 
patients the hazards of an emergency 
considered higher than the risk from t 
infarction. These patients were treated conventionally in the 
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Figure 2. Results of treatment in 27 patients with coronary throm- 
bosis after angioplasty. Abbreviations as in Figure I. 
intensive care unit. All three patients developed cardiac 
enzyme or ECG signs, or both, of a small or moderate 
myocardial infarction. 
Follow-up angiography 24 to 36 h after angioplasty was 
performed in all 22 patients inwhom the vessel was patent at 
discharge from the catheterization laboratory. Reocclusion 
of the dilated vessel was revealed in 12 patients (54.5%) (Fig. 
2), 11 of whom demonstrated cardiac enzyme or ECG signs, 
or both, of a small or moderate myocardial infarction. Only 
5 of the 12 early vessel closures were accompanied by 
symptoms suggestive of myocardial reinfarction. However, 
seven of the 10 remaining patients with a persistently patent 
vessel at follow-up angiography also demonstrated cardiac 
enzyme signs of a small myocardial infarction. 
Adverse ffects. One patient undergoing emergency by- 
pass operation went into cardiogenic shock during the an- 
e persistent patency at 24-36 h follow up ; 0 Persistent occlusion; 
gioplasty procedure. In this patient tbrombo~ysis was 
stopped with aprotinin as described, an 
diately underwent an emergency b pass 0 
small myocardial infarction during the 
complications were observed in 10 patients 
were related to the puncture site in ni 
one patient had massive gum bleeding 
as well as hematemesis after thrombolysis was co 
None of the patients with bleeding com~~icati0~s 
blood transfusion. 
time was ~ro~0~~ed to 
rombolysis, resulting in 
an average prolongation f 181 ? 5.5 s before and 181 ? 
at 120 min into thrombolysis. In the 21 patients in wh 
detailed coagulation a d fibrinolysis analysis was perfor 
plasminogen a d alpha*-antiplasmin levels decreased to 71 2 
44% (p < 0.05) and 51 +. 47.5% (p < 0.05) of the baseline 
values, respectively. Simultanecdusly, average fibrin0 
levels dropped to 94 + 32% of the baseline vahies ( 
whereas D-dimer levels-the specific split products 
linked fibrin-increased from 594 zz 789 to 
&liter (p < 0.01). When the patients were cl 
ing to clinical course (successful treatment 
vessel patency versus nonreopening plus early reocclusion), 
no significant differences were revealed between the two 
groups of patients. 
Thrombin-antith complex levels in the tot 
group of 21 patients from9.1 5 13.6to11.6+ 12 
Ccglliter (Fig. 3). When the patients were separated into two 
groups according to clinical course, the values for the 
thrombin-antithrombin-Ill complex levels between these 
two groups of patients were significantly different. Patients 
with successful thrombolysis and persistent patency demon- 
Figure 3. Thrombin-antithrombin-III 
complex (TAT) levels (&liter) in 27 
patients with thrombotic occlusion 
during coronary angioplasty. Abbrevi- 
ations as in Figure 1. 
to 
6 
3 
6il 120 mm 
standard range 
o reocclusion at 24-36 h follow up 
atients with abru 
combined regimen of i~tracoro~a 
sis together with repeat mild pre 
patency rate X30% was achieve 
catheterization laboratory. 
e l~tervent~on. 
In recent studies in patients with 
more, the thrombi~antithrombin-III complex levels mea- 
sured 2 h after the start of thrombolysis were predictive of 
the short-term clinical course of the patients (9). 
With a view toward elucidating the role of the clotting an 
fibrinolytic syste ed detailed investigations of 
the hemostatic her p~asm~r~ogcn, alpha,- 
in, fibrinogen or -dimer levels were related to 
the clinical course 
samples had not been collected in the presence of specific 
t-t-PA inhibitors, in vitro lysis was not completely precluded. 
Hence, there remains ome uncertainty as to whether the 
high thrombin activities at the 
the coronary thrombus and thus may further enhance appo- 
sitional thrombus growth. Hence, repeated balloon infla- 
tions, as performed inthis study, may interfere with the local 
abolished. In two thirds of the patients with abrupt hrom- 
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botic closure of the coronary artery closely related to 
angioplasty, the current concepts for anticoagulation faitto 
abolish the local procoagulant activities. Thus, local throm- 
bin release is continuously increased and becomes finally 
detectable even in venous blood. In these patients each 
measure undertaken, such as repeat balloon inflations or the 
administration f thrombolytic agents, may promote rather 
than prevent the precipitation f additional thrombotic ma- 
terial. 
Conclusions. In this study, pretreatment of patients with 
aspirin and high dose intravenous heparin frequently failed 
to control the intensifying procoagulant activities causing 
thrombotic o clusion of the dilated coronary artery. It seems 
highly unlikely, therefore, that administering more heparin 
than was given in this study will accomplish therapeutic 
success. Hence, until stronger thrumbin i hibitors like hiru- 
din (21) or stronger platelet inhibitors like glycoprotein 
IIbiIIIa platelet receptor inhibitors (22) are available for 
routine clinical use, the combination of thrombolytic agents 
with repeat balloon inflations should only be considered as 
an intermediate therapy. Because of the high reocclusion 
rate of >50% during the first 36 h of clinical follow-up, even 
those patients in whom reopening of the vessel can be 
achieved should at the present ime undergo immediate 
aortocoronary b pass grafting. We hope that in the near 
future, a prospective variable may be derived from throm- 
bin-antithrombin-III complex measurements upon which an 
individual decision for immediate bypass operation can be 
based. 
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